Welcome to our dedicated page for Krystal Biotech SEC filings (Ticker: KRYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Krystal Biotech's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Krystal Biotech's regulatory disclosures and financial reporting.
Krystal Biotech Chief Accounting Officer Kathryn Romano reported exercising stock options for 12,500 shares of common stock at an exercise price of $63.55 per share on February 9, 2026, then selling the same 12,500 shares in multiple open‑market trades at prices between $270.010 and $277.88 per share. Following these sales, she directly owned 18,568 shares of Krystal Biotech common stock.
The option exercise, share sales, and a 750‑share bona fide gift to a charitable donor‑advised fund were carried out under a pre‑arranged Rule 10b5‑1 trading plan that began on November 6, 2025 and is scheduled to run through August 31, 2026, subject to earlier termination under its terms.
Krystal Biotech common stockholder plans to sell 12,500 shares under Rule 144. The shares are to be sold through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $3,458,250 and 28,997,519 shares of Krystal Biotech common stock shown as outstanding.
The seller acquired these 12,500 shares on 02/09/2026 through the exercise of a stock option originally granted on 02/28/2022, paying cash for the shares. The notice includes a representation that the seller is not aware of any undisclosed material adverse information about Krystal Biotech’s current or prospective operations.
Krystal Biotech furnished preliminary 2025 financial figures ahead of a major healthcare conference. The company expects total net product revenue from its VYJUVEK therapy to be between $106–$107 million for the fourth quarter of 2025 and between $388–$389 million for the full year 2025. Krystal also expects to end 2025 with approximately $955 million in cash, cash equivalents and investments, indicating a substantial liquidity position.
The company’s press release also outlines its rare disease strategic vision, 2026 corporate objectives, and preliminary 2026 combined non-GAAP R&D and SG&A expense guidance. All reported figures are unaudited and subject to change as the year-end 2025 audit is still in progress.
Krystal Biotech reported a positive interim clinical update from its KB407 Phase 1 CORAL-1 study in patients with cystic fibrosis. The company confirmed delivery of wild-type CFTR to the lungs, an important early step for a gene therapy approach targeting the underlying cause of the disease rather than just symptoms.
To explain the interim data and the broader KB407 development program, Krystal Biotech scheduled a conference call and webcast at 4:30 p.m. ET on January 8, 2026. A detailed slide presentation and the full announcement were made available to investors through the company’s website and as accompanying exhibits.
Krystal Biotech furnished an update on its recent performance, announcing financial results for the quarter ended September 30, 2025. The company provided these results via a press release, which is attached as Exhibit 99.1.
The disclosure is furnished under Item 2.02 (Results of Operations and Financial Condition) and is not deemed “filed” for purposes of Section 18 of the Exchange Act. It is also not incorporated by reference into other SEC filings except where expressly stated by specific reference. Krystal Biotech’s common stock trades on the Nasdaq Global Select Market under the symbol KRYS.
Krystal Biotech (KRYS) reported strong Q3 2025 results, driven by continued commercialization of VYJUVEK. Product revenue, net reached $97.8 million, up from $83.8 million a year ago, with a 96% gross margin. Income from operations rose to $41.4 million from $22.5 million. A tax benefit contributed to net income of $79.4 million versus $27.2 million last year, and diluted EPS increased to $2.66 from $0.91.
For the nine months, product revenue, net totaled $282.0 million (vs. $199.4 million), with net income of $153.4 million. The company released $48.4 million of valuation allowance on deferred tax assets, reflecting improved profitability. Liquidity remained solid with $392.6 million in cash and cash equivalents, $338.5 million in short‑term investments, and $133.1 million in long‑term investments as of September 30, 2025.
Accounts receivable were $129.6 million with concentration in two customers (Customer A 71%, Customer B 16%). Shares outstanding were 28,984,000 as of September 30, 2025, and 28,997,519 as of October 29, 2025.
Krystal Biotech (KRYS) announced that its wholly owned subsidiary, Krystal Biotech Japan KK, commenced the commercial launch of VYJUVEK (beremagene geperpavec) in Japan effective October 22, 2025. The launch follows VYJUVEK’s inclusion on Japan’s National Health Insurance Drug Price List the same day, enabling reimbursed access for the treatment of dystrophic epidermolysis bullosa. VYJUVEK is listed at 2,955,232.7 yen per unit. The company stated this information is furnished for informational purposes.
Krystal Biotech (KRYS) 10-Q – Q2 2025 highlights
- Revenue: VYJUVEK® drove net product revenue to $96.0 m (+37% YoY); H1 2025 revenue reached $184.2 m (+60%).
- Profitability: Gross margin held at 93%. Income from operations leapt to $39.3 m (vs $8.6 m), thanks to higher sales and the absence of 2024 litigation charges. Net income was $38.3 m ($1.29 diluted EPS) versus $15.6 m ($0.53).
- Cash & Investments: Cash, cash equivalents and short-term investments rose to $682.0 m; total liquidity including long-term investments is $820.8 m. The company expects current resources to fund operations for ≥12 months.
- Expenses: R&D fell 8% YoY to $14.4 m as manufacturing timing shifted; SG&A climbed 27% to $35.2 m reflecting commercial build-out. No litigation settlement expense this quarter (-$12.5 m YoY).
- Balance sheet: Stockholders’ equity surpassed $1.04 bn. Accounts receivable stood at $111.4 m, with ~78% concentrated in one customer.
- Pipeline progress: Multiple Phase 1/2 studies (KB407 CF, KB408 AATD, KB707 oncology, KB803 & KB801 ophthalmology) are enrolling; first EU & Japan launches of VYJUVEK expected H2 2025.
- Risks: DOJ subpoenas regarding genetic-testing program; outcome unknown. Heavy reliance on single product and customer concentration noted.